AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RHYTHM BIOSCIENCES LTD

0.087

-0.010-10.31%

Volume:546.32K

Turnover:50.60K

Market Cap:30.79M

PE:-4.92

High:0.096

Open:0.096

Low:0.087

Close:0.097

52wk High:0.280

52wk Low:0.075

Shares:353.87M

Float Shares:188.31M

Volume Ratio:1.95

T/O Rate:0.29%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.018

EPS(LYR):-0.014

ROE:-276.00%

ROA:-96.19%

PB:8.46

PE(LYR):-6.12

Loading ...

Overview Company News Filings

We Think Rhythm Biosciences (ASX:RHY) Needs To Drive Business Growth Carefully

Simply Wall St.

Rhythm Biosciences FY Prelim Loss from Ordinary Activities After Tax Attributable A$5.9 Mln

THOMSON REUTERS

Rhythm Biosciences - no Dividends Paid, Recommended or Declared for Fy2026

THOMSON REUTERS

Rhythm Biosciences Announces Appointment of Non-Executive Directors

Rhythm Biosciences - Appoints Maureen Baker and Carl Stubbings as Non-Executive Directors Effective 27 August 2026

THOMSON REUTERS

Rhythm Biosciences geneType PRS cancer risk test joins CancerIQ platform network

Rhythm Biosciences Ltd-Rhyo Underwriting Update

THOMSON REUTERS

Rhythm Biosciences Says Cancer Test Early Commercial Adoption Program Hits Milestone; Shares Jump 5%

MT Newswires Live

Rhythm Biosciences Says Cancer Risk Assessment Test Sale in the Philippines Constitutes First Southeast Asia Sale

MT Newswires Live

Rhythm Biosciences Activates First Commercial Blood Collection Network for Cancer Blood Test Product; Shares Up 3%

MT Newswires Live

Rhythm Biosciences Completes First Sale of Colorectal Cancer Test; Shares Up 13%

MT Newswires Live

Rhythm Biosciences Says Australian Laboratory Accreditation Body Confirms Colorectal Cancer Test Meets Standard; Shares Rise 8%

MT Newswires Live

BRIEF-Rhythm Biosciences Executes Distribution Agreement For Genetype

Rhythm Biosciences Secures Supply Deal With UK Cancer Diagnostics Company

MT Newswires Live

Rhythm Biosciences - Executes Distribution Agreement for Genetype for Southeast Asian Market With Digistain Ltd (UK)

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/RHY.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RHY.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RHY.AU\",,,,,undefined,":{"symbol":"RHY.AU","market":"AU","secType":"STK","nameCN":"RHYTHM BIOSCIENCES LTD","latestPrice":0.087,"timestamp":1788152288281,"preClose":0.097,"halted":0,"volume":546322,"delay":0,"changeRate":-0.10309278350515473,"nameEN":"RHYTHM BIOSCIENCES LTD","floatShares":188306561,"shares":353866857,"eps":-0.0177,"marketStatus":"Trading","change":-0.01,"latestTime":"08-31 14:59:40 AEST","open":0.096,"high":0.096,"low":0.087,"amount":50597,"amplitude":0.092784,"askPrice":0.09,"askSize":36,"bidPrice":0.088,"bidSize":16739,"shortable":3,"etf":0,"ttmEps":-0.0177,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788156000000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.097,"openAndCloseTimeList":[[1788134400000,1788156000000]],"volumeRatio":1.947921,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RHY.AU","preClose":0.099,"auctionPrice":0.098,"auctionVolume":43522,"auction":3,"marketStatus":"盘后竞价","timestamp":1787810917529}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RHY.AU\",,,,,undefined,":{"symbol":"RHY.AU","floatShares":188306561,"roa":"-96.19%","roe":"-276.00%","lyrEps":-0.014222,"volumeRatio":1.947921,"shares":353866857,"dividePrice":0,"high":0.096,"amplitude":0.092784,"preClose":0.097,"low":0.087,"week52Low":0.075,"pbRate":"8.46","psRate":"17.69","week52High":0.28,"institutionHeld":0,"latestPrice":0.087,"committee":0.995708,"eps":-0.0177,"divideRate":0,"volume":546322,"delay":0,"ttmEps":-0.0177,"open":0.096,"prevYearClose":0.135,"prevWeekClose":0.097,"prevMonthClose":0.079,"prevQuarterClose":0.091,"fiveDayClose":0.088,"twentyDayClose":0.081,"sixtyDayClose":0.105,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RHY.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2020-07-27","symbol":"RHY.AU","type":"split","dateTimestamp":1595772000000,"forFactor":875,"toFactor":1000,"ratio":0.875}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RHY.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RHY.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663972019","title":"We Think Rhythm Biosciences (ASX:RHY) Needs To Drive Business Growth Carefully","url":"https://stock-news.laohu8.com/highlight/detail?id=2663972019","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663972019?lang=en_us&edition=fundamental","pubTime":"2026-08-29 07:19","pubTimestamp":1787959158,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-rhy/rhythm-biosciences-shares/news/we-think-rhythm-biosciences-asxrhy-needs-to-drive-business-g","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-rhy/rhythm-biosciences-shares/news/we-think-rhythm-biosciences-asxrhy-needs-to-drive-business-g","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7124","RHY.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662776865","title":"Rhythm Biosciences FY Prelim Loss from Ordinary Activities After Tax Attributable A$5.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662776865","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662776865?lang=en_us&edition=fundamental","pubTime":"2026-08-27 15:05","pubTimestamp":1787814349,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nPLXF8J94Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7124","RHY.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662776847","title":"Rhythm Biosciences - no Dividends Paid, Recommended or Declared for Fy2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662776847","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662776847?lang=en_us&edition=fundamental","pubTime":"2026-08-27 15:05","pubTimestamp":1787814349,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nPLXF8J94Q:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RHY.AU","BK7124"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662276618","title":"Rhythm Biosciences Announces Appointment of Non-Executive Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2662276618","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662276618?lang=en_us&edition=fundamental","pubTime":"2026-08-26 09:32","pubTimestamp":1787707975,"startTime":"0","endTime":"0","summary":"BRIEF-Rhythm Biosciences Announces Appointment Of Non-Executive DirectorsAug 26 (Reuters)-Rhythm Biosciences LtdRHY.AX:APPOINTMENT OF NON-EXECUTIVE DIRECTORSAPPOINTS MAUREEN BAKER AND CARL STUBBINGS AS NON-EXECUTIVE DIRECTORS EFFECTIVE 27 AUGUST 2026Further company coverage:RHY.AX","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nTUE9VN2DS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHY.AU","BK7124"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662793757","title":"Rhythm Biosciences - Appoints Maureen Baker and Carl Stubbings as Non-Executive Directors Effective 27 August 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662793757","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662793757?lang=en_us&edition=fundamental","pubTime":"2026-08-26 06:07","pubTimestamp":1787695629,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUE9VN2DS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RHY.AU","BK7124"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640154700","title":"Rhythm Biosciences geneType PRS cancer risk test joins CancerIQ platform network","url":"https://stock-news.laohu8.com/highlight/detail?id=2640154700","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640154700?lang=en_us&edition=fundamental","pubTime":"2026-06-04 19:37","pubTimestamp":1780573041,"startTime":"0","endTime":"0","summary":"CancerIQ added Rhythm Biosciences’ geneType Cancer Risk Assessment to its platform, expanding ordering access across a network of more than 60 health systems.The test combines a polygenic risk score with clinical and family history to produce 5-year and lifetime risk estimates across six cancers.The rollout targets patients with prior hereditary cancer testing or risk not fully explained by traditional models, supporting more personalized screening decisions.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL4fRhMm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630378848","title":"Rhythm Biosciences Ltd-Rhyo Underwriting Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2630378848","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630378848?lang=en_us&edition=fundamental","pubTime":"2026-04-28 15:24","pubTimestamp":1777361091,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nTUE59VSBT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RHY.AU","BK7124"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623606153","title":"Rhythm Biosciences Says Cancer Test Early Commercial Adoption Program Hits Milestone; Shares Jump 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623606153","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623606153?lang=en_us&edition=fundamental","pubTime":"2026-03-30 11:23","pubTimestamp":1774841006,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  said that its ColoSTAT Access program, which provides a pathway for the early commercial adoption of its ColoSTAT cancer test reached 10 participating clinician sites across Victoria, New South Wales, and Queensland, according to a Monday Australian bourse filing.Meanwhile, an additional 40 blood collection sites were activated as part of its commercial network rollout strategy with its partner 4Cyte Pathology, bringing the total to 78 activated commercial collection centers, per the filing.The company's shares rose past 5% in recent trading on Monday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RHY.AU","BK7124"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622837878","title":"Rhythm Biosciences Says Cancer Risk Assessment Test Sale in the Philippines Constitutes First Southeast Asia Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2622837878","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622837878?lang=en_us&edition=fundamental","pubTime":"2026-03-26 07:44","pubTimestamp":1774482258,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  made a sale of its geneType cancer risk assessment test in Manila, Philippines, the first sale in Southeast Asia, according to a Thursday Australian bourse filing.The firm partnered with Digistain in the region earlier in March. The Digistain team effectively completed the initial commercial pilot and will now scale sales across the Philippines before setting up pilots in other Southeast Asian markets.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RHY.AU","BK7124"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620077024","title":"Rhythm Biosciences Activates First Commercial Blood Collection Network for Cancer Blood Test Product; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620077024","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620077024?lang=en_us&edition=fundamental","pubTime":"2026-03-18 09:23","pubTimestamp":1773796980,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  said it successfully activated its first commercial blood collection network of clinics across major cities, enabling the scaling of cancer blood test, ColoSTAT's commercial testing services, according to a Wednesday Australian bourse filing.The ColoSTAT test is a blood-based test for the detection of colorectal cancer.4Cyte Pathology activated an initial network of 38 blood collection sites across major cities in Queensland, New South Wales, and Victoria, enabling clinician referral and patient access to ColoSTAT testing through an established clinician pathway, the filing added.Clinicians within designated 4Cyte Pathology clinics are being onboarded to provide referrals for ColoSTAT testing, with additional collection sites planned as part of the ongoing commercial rollout, the filing added.The company said immediate scale-up can now proceed directly with physicians and through the ColoSTAT access program using a validated commercial and logistical pathway.The com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7124","RHY.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618960171","title":"Rhythm Biosciences Completes First Sale of Colorectal Cancer Test; Shares Up 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618960171","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618960171?lang=en_us&edition=fundamental","pubTime":"2026-03-11 07:58","pubTimestamp":1773187133,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  completed the first sale of the blood-based ColoSTAT colorectal cancer test, according to a Wednesday filing with the Australian bourse.The company will scale up test volumes directly with physicians and through its ColoSTAT Access Program, the filing said.Shares rose nearly 13% in morning trade Wednesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RHY.AU","BK7124"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618930616","title":"Rhythm Biosciences Says Australian Laboratory Accreditation Body Confirms Colorectal Cancer Test Meets Standard; Shares Rise 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618930616","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618930616?lang=en_us&edition=fundamental","pubTime":"2026-03-09 11:22","pubTimestamp":1773026565,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  said the National Association of Testing Authorities confirmed that its ColoSTAT blood-based colorectal cancer test satisfies all applicable technical and quality requirements under the ISO 15189:2022 standard, according to a Monday Australian bourse filing.The test's validation and intended clinical application were reviewed in accordance with the National Pathology Accreditation Advisory Council requirements. ColoSTAT was formally listed within the accredited scope of Rhythm's laboratory in Parkville, Victoria.Its shares jumped 8% in recent trading on Monday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","RHY.AU","XKO.AU","XAO.AU","SMP","BK7124","BK4124"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616306782","title":"BRIEF-Rhythm Biosciences Executes Distribution Agreement For Genetype","url":"https://stock-news.laohu8.com/highlight/detail?id=2616306782","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616306782?lang=en_us&edition=fundamental","pubTime":"2026-03-04 09:09","pubTimestamp":1772586573,"startTime":"0","endTime":"0","summary":"BRIEF-Rhythm Biosciences Executes Distribution Agreement For GenetypeMarch 4 (Reuters) - Rhythm Biosciences Ltd RHY.AX:EXECUTES DISTRIBUTION AGREEMENT FOR GENETYPE FOR SOUTHEAST ASIAN MARKET WITH DIGISTAIN LTD (UK)Further company coverage: RHY.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nFWN3ZR17M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616306119","title":"Rhythm Biosciences Secures Supply Deal With UK Cancer Diagnostics Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2616306119","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616306119?lang=en_us&edition=fundamental","pubTime":"2026-03-04 09:00","pubTimestamp":1772586033,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  secured an agreement with UK-incorporated cancer diagnostics company Digistain for the supply of its geneType genetic test portfolio, according to a Wednesday filing with the Australian bourse.The deal grants Digistain the right to market and distribute the genetic test portfolio in Southeast Asia for an initial 12-month term, with renewal provisions supporting scalable expansion, the filing said.Revenue is generated per test as samples are processed and reported, with invoicing done monthly and 30-day payment terms, per the filing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7124","RHY.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616372197","title":"Rhythm Biosciences - Executes Distribution Agreement for Genetype for Southeast Asian Market With Digistain Ltd (UK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616372197","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616372197?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:58","pubTimestamp":1772575125,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nFWN3ZR17M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7124","RHY.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}]}}